Key result
Homologous COVID-19 mRNA boosters linked to ~18% fewer systemic reactions versus the second primary dose.
Why the study?
Following FDA authorization and ACIP recommendations for homologous and heterologous COVID-19 vaccine booster doses, the study aimed to characterize booster safety among persons aged 18 years.
Are COVID-19 vaccine booster doses safe and well-tolerated compared to the primary series in adults?
Population
721,562 v-safe registrants aged 18 years receiving a booster dose
Comparison
Booster dose vs dose 2, homologous vs heterologous boosters, and Moderna vs other vaccines
Design
Surveillance study using voluntary smartphone-based (v-safe) and passive (VAERS) safety systems
Authors
Loading...
Fewer reactions after homologous boosters support tolerability; leaves open questions on heterologous regimens and broader populations.
Observational (n=721,562)
Are COVID-19 vaccine booster doses safe and well-tolerated compared to the primary series in adults?
Absolute Event Rate: 64.4% vs 78.4%
p-value: p=<0.001
Homologous COVID-19 mRNA booster doses are associated with fewer systemic reactions compared to the second dose of the primary series.
Hause et al. (2022) conducted an observational in COVID-19 Vaccination (n=721,562). Homologous COVID-19 mRNA vaccine booster (Moderna) vs. Second primary dose (Dose 2) was evaluated on Systemic reactions during the week following vaccination (p=<0.001). Homologous COVID-19 mRNA vaccine booster doses resulted in significantly less frequent local and systemic reactions compared to the second primary vaccine dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: